Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis-HIV-co-infected patients in resource-constrained settings

AIDS. 2006 Jan 9;20(2):302-3. doi: 10.1097/01.aids.0000202652.49020.94.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • Antibiotics, Antitubercular / adverse effects
  • Developing Countries
  • Drug Therapy, Combination
  • HIV Protease Inhibitors / adverse effects*
  • Humans
  • Rifampin / adverse effects
  • Ritonavir / adverse effects*
  • Saquinavir / adverse effects*
  • Tuberculosis / drug therapy*

Substances

  • Antibiotics, Antitubercular
  • HIV Protease Inhibitors
  • Saquinavir
  • Ritonavir
  • Rifampin